secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001213900-25-043290
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago
--------------------------------------------------------------------------------

- Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).
- Net income $1.4M ($0.16 diluted EPS) vs net loss of $438K ($0.06 loss) in Q1 2024.
- Gross margin improved to 42% from 32% YoY; adjusted EBITDA $2.3M for Q1.
- Cash $4.6M, no draw on $1M line; working capital $12.1M, equity $29M.
- Contract manufacturer issues delay Re-Tain; company exploring strategic options for the technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390025043290/0001213900-25-043290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390025043290/ea0241943-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer